Seoul – September 20, 2026 -- NAVER D2SF, the in-house corporate venture arm of NAVER, has joined a $10 million Series A2 bridge round for Silicon Valley-based precision medicine company ImpriMed, backing its push toward U.S. regulatory clearance and Asian market expansion.